Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports
|
|
- Julianna Golden
- 5 years ago
- Views:
Transcription
1 468627TAK Therapeutic Advances in Cardiovascular DiseaseJJ DiNicolantonio and VL Serebruany 2012 Therapeutic Advances in Cardiovascular Disease Editorial Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports James J. DiNicolantonio and Victor L. Serebruany Ther Adv Cardiovasc Dis (2013) 7(1) 5 9 DOI: / The Author(s), Reprints and permissions: journalspermissions.nav Ticagrelor is a new antiplatelet agent chemically known as a cyclopentyltriazolopyrimidine, with distinguishing properties from that of theinopyridines. Theoretically in acute coronary syndrome (ACS) a rapid acting antiplatelet agent such as ticagrelor, with a greater inhibition of platelet activation, should improve outcomes. Thus, ticagrelor was tested against clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial, which was a phase III, randomized, double-blind, parallel-group, multinational, clinical study of 18,624 patients with moderate- to high-risk ACS undergoing coronary intervention [Wallentin et al. 2009]. Patients were randomized to ticagrelor 180 mg loading dose followed by 90 mg twice daily thereafter, or clopidogrel mg loading dose followed by 75 mg once daily for 6 12 months [Wallentin et al. 2009]. The primary endpoint was the time of the first event of death from vascular causes, myocardial infarction or stroke, and occurred in 11.7% of patients treated with clopidogrel versus 9.8% of patients randomized to ticagrelor, representing a highly significant benefit for ticagrelor [hazard ratio (HR) 0.84; 95% confidence interval (CI) ; p < 0.001] [Wallentin et al. 2009]. Importantly, the benefit of ticagrelor was driven equally by the reduction of vascular death (p < 0.001) and myocardial infarction (p < 0.005) with 89 events favoring ticagrelor each, but not stroke (p = 0.22) with 19 less events in the clopidogrel arm [Wallentin et al. 2009]. However, such an overoptimistic interpretation of the ticagrelor efficacy has been somewhat clouded by the repeated US Food and Drug Administration (FDA) reviews [FDA, 2011, 2012], suggesting multiple safety issues with ticagrelor. We will be focusing on some major safety issues outlined in the FDA publications. Race and gender The PLATO trial enrolled over a thousand (1081) patients of Chinese or Japanese descent [FDA, 2011, 2012]. Importantly, Japanese patients experienced a 40% greater exposure to ticagrelor versus Caucasians, which was shown in an 8-day phase I study [both for maximum concentration (Cmax) and for under the curve (AUC)] [FDA, 2012]. While there are insufficient safety data in this subgroup, Japanese patients may have an increased risk for overdosing on ticagrelor compared with their white counterparts. However, data are lacking to confirm that higher exposure to ticagrelor in Japanese patients leads to an increased risk of hemorrhagic events. Moreover, women on ticagrelor tended to have more adverse events (AEs), including serious AEs (SAEs), increased discontinuation because of AEs and an increased risk of death compared with men, also suggesting potential overdosing [FDA, 2012]. Whether these differences were statistically significant was not mentioned in the FDA complete response review (CRR) [FDA, 2011]. Bleeding The primary safety concern with ticagrelor in the PLATO trial is bleeding. The FDA CRR indicates that nonprocedural bleeding events were significantly increased after ticagrelor versus clopidogrel [major + minor + minimal: 24.3% versus 15.9%, HR 1.62, 95% CI ); major + minor: 5.9% versus 4.3%, HR 1.39, 95% CI ; major: 3.1% versus 2.3%, HR 1.31, 95% CI ) with a nonsignificant 9% increase in major life-threatening or fatal bleeds (1.3% versus 1.2%, HR 1.09, 95% CI ) and fatal bleeds (0.2% versus 0.2%, HR 1.09, 95% CI ) respectively [FDA, 2011]. Thus, ticagrelor significantly increases major, minor and minimal nonprocedural bleeds compared with clopidogrel. Furthermore, major bleeds were predominately coronary artery bypass graft (CABG)-related bleeding complications (~67%) [FDA, 2011]. However, in PLATO, the reporting of (CABG) bleeds and procedural hemorrhages was set up in Correspondence to: James J. DiNicolantonio, Pharm.D. Wegmans Pharmacy, 500 South Meadow Street, Ithaca, NY 14850, USA jjdinicol@gmail.com Victor L. Serebruany, MD, PhD HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD, USA 5
2 Therapeutic Advances in Cardiovascular Disease 7 (1) ticagrelor s favor. Indeed, the reporting of procedural bleeds was set up to be related to the procedure rather than the study drug. The protocol stated that procedural bleeding should not be reported as an AE if it is expected during the procedure, yet there was no guidance on the form about what is expected during the procedure [FDA, 2011]. Furthermore, on the AE form, the checkbox for Bleed is related to a procedure and does not represent an adverse event did not allow the severity of the bleed (minimal, minor or major) to be recorded and the remainder of the AE form was not to be completed. However, the reporting of CABG-related bleeds was set up to document as much as possible (i.e. the electronic case report form system automatically created a bleed event form for all CABG forms) as the CABG-related checkbox also had minimal, minor and major bleeding severity checkboxes (unlike the reporting for procedural bleeds) [FDA, 2011]. Moreover, the investigator was to complete the rest of the AE form for CABGrelated bleeds, which was not required for procedural-related bleeds [FDA, 2011]. As ticagrelor has a faster offset, one would expect fewer CABG bleeds but more procedural-related bleeds due to ticagrelor s higher inhibition of platelet activity compared with clopidogrel. Thus, it seems that the PLATO investigators stacked the deck of cards in ticagrelor s favor (i.e. reporting more CABG bleeds but fewer procedural bleeds). Despite this ploy, the risk of CABG bleeding was increased in patients receiving ticagrelor compared with clopidogrel-treated patients in those who did not wait until day 5 after stopping treatment, which is recommended in ACS guidelines [FDA, 2011; Levine et al. 2011]. Thus, the antiplatelet effects of ticagrelor last significantly longer than predicted by its pharmacokinetics/pharmacodynamics. In addition, the purported faster offset of ticagrelor (compared with clopidogrel) is not clinically relevant as it does not translate into fewer bleeding events. There were statistically more overall bleeds (PLATO-defined major, lifethreatening or fatal, minor and minimal) in the ticagrelor arm [FDA, 2011]. In summary, in patients treated with ticagrelor, clinicians should consider delaying CABG and other major surgeries until 5 days after cessation of therapy. Strokes and embolic events There were more intracranial bleeds on ticagrelor compared with clopidogrel [27 (0.3%) versus 14 (0.2%), relative risk (RR) 1.90, p value not stated; one extra intracranial bleed for every 1000 patients treated] and more hemorrhagic strokes (26 versus 16, RR 1.63, p value not given) with 11 (0.12%) fatal hemorrhagic strokes on ticagrelor versus only 1 (0.0%) on clopidogrel (i.e. there was a 10-fold increase in fatal hemorrhagic strokes with ticagrelor versus clopidogrel; p = 0.02) [FDA, 2011]. Furthermore, for every 10 all-cause deaths avoided with ticagrelor, there was one extra hemorrhagic stroke death [FDA, 2011]. A higher degree of platelet inhibition with ticagrelor may precipitate a clinical hemorrhagic event in someone with a subclinical stroke compared with someone on clopidogrel. Supporting this theory was the significant increase in intracranial hemorrhages (ICHs) on ticagrelor compared with clopidogrel (27 versus 14) as well as fatal ICH [11 (0.1%) versus 2 (0.0%), RR 5.47; 1 extra fatal ICH for every 1000 patients treated with ticagrelor]. Moreover, peripheral vascular disease was increased by 17% (RR 1.17, 155 versus 132), thromboembolic disease (arterial and venous) was increased by 24% (RR 1.24, 84 versus 68), any venous thrombotic event was increased by 11% (RR 1.11, 72 versus 65), deep vein thrombosis was increased by 11% (RR 1.11, 72 versus 65) and pulmonary embolism was increased by 46% (35 versus 24) with ticagrelor compared with clopidogrel (Table 1) [FDA, 2011]. A higher platelet inhibition may lead to clots that are more brittle and thus more likely to embolize on ticagrelor. Another explanation purported by the FDA document was that ticagrelor may increase the risk for plaque rupture and subsequent embolization further downstream in the vasculature. In summary, a higher antiplatelet potency and faster antiplatelet offset with ticagrelor does not seem to give it a clinical advantage with regard to reduced embolic events or reduced hemorrhagic events. Dyspnea Shortness of breath or dyspnea was reported more frequently with ticagrelor compared with clopidogrel (14.49% versus 8.78%, RR 1.6, p value not stated), with one-third of patients experiencing dyspnea throughout study termination [FDA, 2011]. Thus, one out of three patients experiencing dyspnea on ticagrelor will continue to have this serious adverse event for a prolonged period of time. Moreover, dyspnea leading to discontinuation was nine times higher 6
3 JJ DiNicolantonio and VL Serebruany Table 1. Embolic/vascular events: ticagrelor compared with clopidogrel [FDA, 2011]. Event Ticagrelor Clopidogrel RR Amaurosis fugax Stroke Intracranial hemorrhage Stroke/TIA Cerebrovascular and carotid disease Thromboembolic disease (arterial and venous) Peripheral vascular disease Necrotic limb/amputation Venous event DVT PE DVT, deep vein thrombosis; PE, pulmonary embolism; RR, relative risk; TIA, transient ischemic attack. with ticagrelor versus clopidogrel (0.9% versus 0.1%, RR and p value not given). Discontinuation for dyspnea (from sponsor) indicated an almost eightfold increase with ticagrelor versus clopidogrel [77 (0.8%) versus 10 (0.1%), RR 7.66] [FDA, 2011]. Thus, the reported side effect of dyspnea with ticagrelor seems to be more clinically relevant than originally stated [Wallentin et al. 2009; FDA, 2011]. While a pulmonary function substudy was performed, flaws in its design, conduct and analysis prevented any ascertainment of conclusions. High baseline smoking status as well as lack of the preferential inclusion of individuals who experienced dyspnea on ticagrelor may have suppressed a difference, even if one had existed [FDA, 2011]. Gynecomastia While the absolute rate of gynecomastia was low (approximately 3 per 1000 men at 1 year), ticagrelor significantly increased gynecomastia 5.3 fold compared with clopidogrel [15 (0.16%) versus 3 (0.03%), RR > 5.0]. Thus, in patients experiencing or having a history of gynecomastia, clopidogrel may be preferred. Arrhythmias and bradycardia The DISPERSE 2 trial, a phase II trial comparing two doses of ticagrelor versus clopidogrel in 990 patients, indicated a higher frequency of arrhythmias with ticagrelor [FDA, 2011]. In PLATO, while there were more atrial arrhythmias and ventricular pauses with ticagrelor versus clopidogrel, a somewhat favorable effect was seen for sudden death and ventricular arrhythmias [FDA, 2011]. However, PLATO excluded patients at increased risk of bradycardic events as ticagrelor was shown to significantly increase this side effect compared with clopidogrel in the DISPERSE 2 trial [FDA, 2011]. Thus, patients at risk of a bradycardia should not be placed on ticagrelor. History of hepatic disorder Approximately 400 patients with a history of baseline hepatic disorder were enrolled in the PLATO trial [FDA, 2011]. In these individuals, compared with clopidogrel, ticagrelor significantly increased death by over threefold (3.1% versus 0.9%), and frequency of SAEs (20.4% versus 16.6%) and AEs (84.2% versus 81.1%). Moreover, ticagrelor increased major bleeds compared with clopidogrel in these individuals (11.2% versus 8.7%) [FDA, 2011]. In summary, clinicians should use caution when prescribing ticagrelor in patients with a history of hepatic disorder. Renal insufficiency Compared with clopidogrel, patients receiving ticagrelor with a baseline estimated glomerular 7
4 Therapeutic Advances in Cardiovascular Disease 7 (1) filtration rate (egfr) of less than 30 ml/min had an increased risk of major bleeding complications [23 (19%) versus 16 (11.3%)], death [31 (26.5%) versus 34 (23.4%)] and renal failure [12 (13.6%) versus 5 (5.4%)] respectively. This contrasts with a recent publication by James and colleagues, indicating that a cohort of 214 patients with calculated creatinine clearance less than 30 ml/min showed similar results for the primary composite endpoint, 28.9% per 12 months (27 patients) for ticagrelor versus 39.0% (39 patients) for clopidogrel (HR 0.77; 95% CI ), and for mortality, 23.4% (21 patients) versus 29.6% (29 patients) (HR 0.77; 95% CI ) [FDA, 2011; James et al. 2010]. Thus, in patients with a baseline egfr less than 30 ml/min, ticagrelor may have a net clinical harm compared with clopidogrel. Drug interactions Ticagrelor is a cytochrome P450 (CYP)-3A4 substrate and a relatively weak CYP3A4 inhibitor, increasing the exposure of simvastatin (50%, up to two- to threefold in some individuals), atorvastatin (36%), lovastatin (similar to simvastatin) and estradiol (30% in Cmax and 20% in AUC) [FDA, 2011]. CYP3A inducers such as rifampin, dexamethasone, phenytoin, carbamazepine and phenobarbital increase ticagrelor s clearance by 110%. Thus, patients on CYP3A inducers may have less benefit on ticagrelor. In summary, CYP3A4 inhibitors, inducers and substrates need to be given with caution with concomitant ticagrelor administration. Moreover, ticagrelor inhibits the p-glycoprotein (PgP) efflux pump and can significantly increase digoxin levels (75% increase in Cmax, 28% increase in AUC; mean digoxin trough levels increased by 30%, with some individual maximum increases of up to twofold). Thus, in patients on ticagrelor, digoxin concentrations should be monitored closely. Furthermore, concomitant use of ticagrelor and other PgP inhibitors such as verapamil, quinidine and cyclosporine should be used with caution. Despite the favorable efficacy of ticagrelor versus clopidogrel, there are a plethora of subgroups and clinical scenarios in which the safety of ticagrelor may outweigh its benefit (Table 2). When prescribing ticagrelor, clinicians should be fully aware of these potential harmful scenarios, and have an action plan in case adverse events emerge. While ticagrelor has very limited (if any) real-world Table 2. Scenarios in which ticagrelor safety may outweigh benefit [FDA, 2011; EMA, 2010]. CYP3A4 substrates, inhibitors and inducers PgP substrates/inhibitors digoxin, cyclosporine and verapamil Women and Japanese Baseline GFR < 30 ml/min History of cerebrovascular disease History of a thromboembolic event History of ICH History of Hepatic disease Patients at risk of bradycardia CYP3A4, cytochrome P450 3A4; GFR, glomerular filtration rate; ICH, intracranial hemorrhage; PgP, P glycoprotein. experience, the progressive years of its inclusion in the ACS preventive cocktail should allow us to better gleam its overall efficacy and safety profile. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Conflict of interest statement The authors declare no conflicts of interest in preparing this article. References EMA (2010) Ticagrelor (Brilique) Summary of product characteristics. European Medicines Agency. Available at: library/epar_-_product_information/human/001241/ WC pdf (accessed 10 May 2012). FDA (2011) Complete response review. Drug approval package. US Food and Drug Administration. Available at: drugsatfda_docs/nda/2011/022433orig1s000toc. cfm (accessed 5 November 2012). FDA (2012) Ticagrelor Advisory Committee Briefing Document. US Food and Drug Administration. Available at: AdvisoryCommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/ UCM pdf (accessed 10 May 2012). James, S., Budaj, A., Aylward, P., Buck, K., Cannon, C., Cornel, J. et al. (2010) Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition 8
5 JJ DiNicolantonio and VL Serebruany and Patient Outcomes (PLATO) trial. Circulation 122: Levine, G., Bates, E., Blankenship, J., Bailey, S. and Bittl, J. (2011) ACCF/AHA/SCAI guidelines for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 124: e574 e651. Wallentin, L., Becker, R., Budaj, A., Cannon, C., Emanuelsson, H., Held, C. et al.; the PLATO Investigators (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 61: Visit SAGE journals online SAGE journals 9
Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial
compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationTicagrelor (Brilinta), an Antiplatelet Drug for Acute Coronary Syndrome
DrUG FOrECAST Ticagrelor (Brilinta), an Antiplatelet Drug for Acute Coronary Syndrome raeanne Fuller, PharmD; and Benjamin Chavez, PharmD, BCPP INTRODUCTION Acute coronary syndrome (ACS) comprises myocardial
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationPRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome
CEDAC FINAL RECOMMENDATION PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION Edoxaban (Lixiana SERVIER Canada Inc.) Indication: Prevention of Stroke and Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 2.9: Antiplatelet Drugs Aspirin 75mg Dispersible Tablets Aspirin 300mg Dispersible Tablets Aspirin 300mg Suppositories Clopidogrel 75mg Tablets Dipyridamole
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationתרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice)
Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) This drug has been reviewed because it is a product that may be prescribed in primary
More informationMortality. p =
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationNew Study Presented at American Heart Association (AHA) Scientific Sessions 2016:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com New Study Presented at American Heart Association (AHA) Scientific Sessions
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationPrasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives
Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest
More informationBayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com New Late-Breaking Study Data Presented at ACC.17:
More informationBayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationOral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor
Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor Nicolas W. Shammas, MS, MD, FACC Coronary and Peripheral Interventionalist Cardiovascular Medicine, PC Research Director,
More informationNews Release. For UK Media
News Release For UK Media Bayer plc 400 South Oak Way Reading RG2 6AD www.bayer.co.uk Bayer s Xarelto (rivaroxaban) in combination with single antiplatelet therapy receives positive CHMP opinion for treatment
More informationBayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer submits application for marketing approval of rivaroxaban for patients
More informationC. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School
Novel Strategies to Prevent Pulmonary Embolism and DVT: APEX Trial and Substudies C. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School Conflict of Interest Statement 2 Present Research/Grant
More informationTriple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health
Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Brilique 60 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 60 mg ticagrelor.
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationTicagrelor vs prasugrel in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention
DISCLOSURES: NONE Ticagrelor vs prasugrel in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention I. Xanthopoulou, KC. Theodoropoulos, G. Kassimis, V.
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationUPDATES FROM THE 2018 ANTIPLATELET GUIDELINES
UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 21st Annual Contemporary Therapeutic Issues in
More informationBRILINTA (ticagrelor) Tablets
2569300 BRILINTA (ticagrelor) Tablets HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BRILINTA safely and effectively. See full prescribing information
More informationBenefit-Risk Assessment via Case Studies: Key Considerations & Best Practices
Benefit-Risk Assessment via Case Studies: Key Considerations & Best Practices George Quartey (PhD), Genentech Inc. (Acknowledgements: Qi Jiang, Amgen & Weili He, Merck) EFSPI Regulatory Statistics Meeting,
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationDurlaza. Durlaza (aspirin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.13 Subject: Durlaza Page: 1 of 4 Last Review Date: September 15, 2016 Durlaza Description Durlaza
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationDebate Continues on Ticagrelor in PLATO
Debate Continues on Ticagrelor in PLATO www.medscape.com Lisa Nainggolan March 14, 2011 March 11, 2011 (Durham, North Carolina) AstraZeneca should conduct a second trial with its investigational antiplatelet
More informationImpact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy
Impact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy Lars Wallentin, Stefan James, Robert F Storey, Martin Armstrong, Bryan
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationINDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationSupplementary Online Content
Supplementary Online Content Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GYH. Assessment of the CHA 2 DS 2 -VASc score in predicting ischemic stroke, thromboembolism, and death
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationTable S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture
Technical Appendix Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture and Associated Surgical Treatment ICD 9 Code Descriptions Hip Fracture 820.XX Fracture neck of femur 821.XX
More informationAll medications are a double-edged sword with risks
Menopause: The Journal of The North American Menopause Society Vol. 14, No. 5, pp. 1/14 DOI: 10.1097/gme.0b013e31802e8508 * 2007 by The North American Menopause Society REVIEW ARTICLE Postmenopausal hormone
More informationRecombinant Factor VIIa for Intracerebral Hemorrhage
Recombinant Factor VIIa for Intracerebral Hemorrhage January 24, 2006 Justin Lee Pharmacy Resident University Health Network Outline 1. Introduction to patient case 2. Overview of intracerebral hemorrhage
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationAtrial fibrillation (AF) is the most common sustained
New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation At a Glance Practical Implications p 270 Author Information p 281 Full text and PDF www.ajpblive.com Review Article Daniel E. Hilleman,
More informationCHOLESTEROL-LOWERING THERAPHY
CHOLESTEROL-LOWERING THERAPHY TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 50,194 15,036 30.0% 60.8 3.2 1/ 6 (16.7%) HR
More informationUS DOSAGE AND ADMINISTRATION HIGHLIGHTS OF PRESCRIBING INFORMATION
US-9229 ------------------------- DOSAGE AND ADMINISTRATION -------------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION Initiate treatment with 180 mg oral loading dose following an ACS event. Continue
More informationQuale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationNew Data Reaffirm Positive Benefit-Risk Balance of Bayer s Xarelto in Patients with Atrial Fibrillation in Daily Clinical Practice
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com 12 th Annual Congress of the European Cardiac Arrhythmia Society (ECAS) 2016:
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More information2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationAnticoagulation, atrial fibrillation in elderly patients with chronic kidney disease
Anticoagulation, atrial fibrillation in elderly patients with chronic kidney disease Zbigniew Heleniak M.D. Ph.D. Department of Nephrology, Transplantology and Internal Medicine Medical University of Gdansk
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION TICAGRELOR (Brilinta AstraZeneca Canada Inc.) Indication: Secondary Prevention of Atherothrombotic Events Recommendation: The CADTH Canadian Drug
More informationAm J Nephrol 2018;47:67 71 DOI: /
American Journal of Nephrology Original Report: Patient-Oriented, Translational Research Received: November 30, 2017 Accepted: January 6, 2018 Published online: February 1, 2018 Prevalence of Chronic Kidney
More informationTroponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy. Ziad Hijazi, MD
Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy Ziad Hijazi, MD Uppsala Clinical Research Center (UCR) Uppsala University, Sweden Co-authors:
More informationSTEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationa. Ischemic stroke An acute focal infarction of the brain or retina (and does not include anterior ischemic optic neuropathy (AION)).
12.0 Outcomes 12.1 Definitions 12.1.1 Neurologic Outcome Events a. Ischemic stroke An acute focal infarction of the brain or retina (and does not include anterior ischemic optic neuropathy (AION)). Criteria:
More information'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationBayer s Xarelto (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS Study
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Secondary Prevention of Acute Coronary Syndrome (ACS): Bayer s Xarelto (Rivaroxaban)
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients
More informationSubclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study Meagan Sullivan, PharmD PGY2 Cardiology Pharmacy Resident University of Chicago Medicine
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Possia 90 mg film coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 90 mg ticagrelor.
More informationThe PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease
Cardiovasc Drugs Ther (2017) 31:433 444 DOI 10.1007/s10557-017-6749-7 REVIEW ARTICLE The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease Paul P.
More informationSAFE study A-fib ED Anticoagulation Package
SAFE study A-fib ED Anticoagulation Package In this package you will find documents to help you make decision making easy for the Anticoagulation of New AFib patients being discharged from the ED: 1. Anticoagulation
More information